Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.

about

Prolonged diabetic ketoacidosis associated with canagliflozin.Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature

P2860

Q55048274-78B7F839-F4D6-4EC0-A1EC-B423E0796483 Q58589690-E3642E0D-390F-4BC0-AF63-5B76906C8EC1

P2860

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.

Item

http://www.wikidata.org/entity/Q42206175

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@en

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@nl

type

Item

label

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@en

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@nl

prefLabel

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@en

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@nl

P1476

Euglycemic Diabetic Ketoacidos ...... Cotransporter-2 Canagliflozin.

@en

P2093

Chelsea A Baker

http://www.w3.org/2001/XMLSchema#string

Daniel A Kelmenson

http://www.w3.org/2001/XMLSchema#string

Kelsey Burr

http://www.w3.org/2001/XMLSchema#string

Neda Rasouli

http://www.w3.org/2001/XMLSchema#string

Paul Reynolds

http://www.w3.org/2001/XMLSchema#string

Yusra Azhar

http://www.w3.org/2001/XMLSchema#string

P2860

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.

8. Pharmacologic Approaches to Glycemic Treatment.

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

SGLT2 Inhibitors and the Diabetic Kidney.

P304

2324709617712736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1177/2324709617712736

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28634592

http://www.w3.org/2001/XMLSchema#string

P921

ketoacidosis

P932

5468766

http://www.w3.org/2001/XMLSchema#string

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.

about

P2860

P2860

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932